Reason for request
Re-assessment of the actual benefit at the request of the Transparency
Clinical Benefit
| Low |
Le service médical rendu par MEGACE 160 mg est faible dans le traitement palliatif des carcinomes du sein.
|
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
VTRFK3DtftGx8wks
Listen
